(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.42%) $924.40
(0.38%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
2.42% HKD 11.02
Live Chart Being Loaded With Signals
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally...
Stats | |
---|---|
Dagens volum | 13.92M |
Gjennomsnittsvolum | 12.73M |
Markedsverdi | 23.16B |
EPS | HKD0 ( 2024-03-29 ) |
Neste inntjeningsdato | ( HKD0 ) 2024-05-17 |
Last Dividend | HKD0.0120 ( 2017-06-05 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -31.49 |
ATR14 | HKD0.0170 (0.15%) |
Volum Korrelasjon
Genscript Biotech Corp Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Genscript Biotech Corp Korrelasjon - Valuta/Råvare
Genscript Biotech Corp Økonomi
Annual | 2023 |
Omsetning: | HKD839.53M |
Bruttogevinst: | HKD409.55M (48.78 %) |
EPS: | HKD-0.0453 |
FY | 2023 |
Omsetning: | HKD839.53M |
Bruttogevinst: | HKD409.55M (48.78 %) |
EPS: | HKD-0.0453 |
FY | 2022 |
Omsetning: | HKD625.70M |
Bruttogevinst: | HKD304.08M (48.60 %) |
EPS: | HKD-0.110 |
FY | 2021 |
Omsetning: | HKD510.60M |
Bruttogevinst: | HKD303.02M (59.35 %) |
EPS: | HKD-0.171 |
Financial Reports:
No articles found.
Genscript Biotech Corp Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
First Dividend | HKD0.0120 | 2017-06-05 |
Last Dividend | HKD0.0120 | 2017-06-05 |
Next Dividend | HKD0 | N/A |
Payout Date | 2017-06-21 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | HKD0.0120 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.29 | -- |
Div. Sustainability Score | 2.51 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0.935 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2230.HK | Ex Dividend Knight | 2023-09-21 | Semi-Annually | 0 | 0.00% | |
1243.HK | Ex Dividend Junior | 2023-08-25 | Annually | 0 | 0.00% | |
0308.HK | Ex Dividend Junior | 2023-09-18 | Annually | 0 | 0.00% | |
3993.HK | Ex Dividend Junior | 2023-06-29 | Annually | 0 | 0.00% | |
1800.HK | Ex Dividend Junior | 2023-06-20 | Annually | 0 | 0.00% | |
0836.HK | Ex Dividend Knight | 2023-09-05 | Semi-Annually | 0 | 0.00% | |
0002.HK | Ex Dividend Knight | 2023-09-04 | Quarterly | 0 | 0.00% | |
2382.HK | Ex Dividend Junior | 2023-05-30 | Annually | 0 | 0.00% | |
1373.HK | Ex Dividend Knight | 2023-10-04 | Semi-Annually | 0 | 0.00% | |
0435.HK | Ex Dividend Knight | 2023-09-21 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.114 | 1.500 | -2.27 | -3.41 | [0 - 0.5] |
returnOnAssetsTTM | -0.0282 | 1.200 | -0.940 | -1.127 | [0 - 0.3] |
returnOnEquityTTM | -0.0695 | 1.500 | -1.884 | -2.83 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.76 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.34 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.92 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.123 | -1.500 | 7.95 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.144 | 2.00 | -0.0480 | -0.0959 | [0 - 30] |
freeCashFlowPerShareTTM | -0.273 | 2.00 | -0.136 | -0.273 | [0 - 20] |
debtEquityRatioTTM | 0.300 | -1.500 | 8.80 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.488 | 1.000 | 5.20 | 5.20 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.495 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.688 | 1.000 | -4.93 | -4.93 | [0.2 - 2] |
assetTurnoverTTM | 0.248 | 0.800 | -1.681 | -1.345 | [0.5 - 2] |
Total Score | 2.51 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -29.39 | 1.000 | -3.07 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0695 | 2.50 | -1.211 | -2.83 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.273 | 2.00 | -0.0909 | -0.273 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.144 | 2.00 | -0.0480 | -0.0959 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 72.26 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.342 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -0.638 |
Genscript Biotech Corp
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.